The Hold rating maintained by Needham analyst Joseph Stringer on Lexicon Pharmaceuticals indicates a neutral outlook for the stock in the short term. This rating suggests that the stock is fairly valued and there is no strong catalyst for significant price movement in either direction. As a result, the short-term impact on LXRX's stock price is expected to be neutral.